He KD, Leonard SM, Mezochow A, Bermudez C, Courtwright A, Blumberg E. Impact of Donor Radiographic Pneumonia on Posttransplant Recipient Outcomes and Microbiology , Transpl Infect Dis: 2026

Mezochow AK, Clausen E, Whitaker K, Claridge T, Blumberg E, Courtwright AM. Letermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients , Am J Transplant: 2025

Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa C, Njei B, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data , JAMA Intern Med, 184: 2024,943-952

Mezochow AK, He KD, Whitaker K, Blumberg E, Crespo MM, Courtwright A. Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review , JHLT Open, 6: 2024,100149

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa C, Njei B, Roy JA, Taddei TH, Justice AC, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status , Pharmacoepidemiol Drug Saf: 2024

Mezochow AK, Schaubel DE, Peyster EG, Lewis JD, Goldberg DS, Bittermann T. Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries , Transpl Infect Dis: 2024

Mezochow AK, Anesi J, West S, Hasz R, Edwards J, Blumberg EA. COVID-19 in organ donors: An organ procurement organization perspective , Transpl Infect Dis: 2024

Mezochow A, Anesi JA. The intricate interplay of immunosuppression and outcomes following Gram-negative bloodstream infection in solid organ transplantation , Transpl Infect Dis: 2022

Mezochow AK, Abt PL, Bittermann T. Differences in Early Immunosuppressive Therapy Among Liver Retransplantation Recipients in a National Cohort , Transplantation, 105: 2021,1800-1807

Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation , J Hepatol: 2021